Overview

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well giving high dose busulfan together with bortezomib works in treating patients with high risk multiple myeloma undergoing stem cell transplant. Drugs used in chemotherapy, such as busulfan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cells growth. Giving busulfan together with bortezomib before a stem cell transplant may kill more cancer cells
Phase:
Phase 2
Details
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antilymphocyte Serum
Bortezomib
Busulfan
Everolimus
Fludarabine
Fludarabine phosphate
Immunoglobulins
Sirolimus
Tacrolimus
Thymoglobulin
Vidarabine